Evidence map›Paper›PMID 40943533›Full record

ArticleInternational journal of molecular sciences2025

Swiprosin-1 Negatively Regulates Osteoclast Differentiation and Bone Resorption via Akt/MAPK/NF-κB Pathway and αvβ3 Integrin-Dependent Signaling.

Yoon-Hee Cheon, Sung Chul Kwak, Chong Hyuk Chung, Chang Hoon Lee, Myeung Su Lee, Ju-Young Kim

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Myeloid-Specific Deletion ofBiomedicines · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoon-Hee CheonMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Sung Chul KwakMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Chong Hyuk ChungMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.ORCID 0000-0001-5806-0733
Chang Hoon LeeMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Myeung Su LeeMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Ju-Young KimMusculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.ORCID 0000-0002-4493-0264

Funding

Korea Health Industry Development Institute RS-2023-KH139410National Research Foundation of Korea RS-2023-00250243
6 · The paper itself

Abstract

Swiprosin-1 (SWS1/EFhd2) is a calcium-binding adaptor protein involved in cytoskeletal regulation, but its physiological role in bone homeostasis remains largely undefined. To elucidate its function in osteoclast biology, we examined SWS1 expression and activity during osteoclastogenesis using primary murine bone marrow-derived macrophages, siRNA-mediated knockdown, and SWS1 knockout (KO) mice. SWS1 was predominantly localized to the nucleus in precursor cells and redistributed to the F-actin ring in mature osteoclasts. Receptor activator of nuclear factor-kappa B ligand stimulation significantly downregulated SWS1 mRNA expression. Loss of SWS1 enhanced osteoclast formation, F-actin ring integrity, and bone resorption, accompanied by elevated expression of osteoclastogenic markers. In vivo, male SWS1 KO mice exhibited deteriorated trabecular bone microarchitecture with increased osteoclast numbers. Mechanistically, SWS1 deficiency intensified αvβ3 integrin-associated cytoskeletal signaling and upregulated Akt, MAPK, NF-κB, and PLCγ2 pathways. These results indicate that SWS1 negatively regulates osteoclast differentiation and function by restraining cytoskeletal reorganization and downstream signaling. Collectively, our findings establish SWS1 as a novel modulator of osteoclast activity and a potential therapeutic target for osteolytic bone disorders.

Indexed as

Bone ResorptionCell DifferentiationIntegrin alphaVbeta3OsteoclastsProto-Oncogene Proteins c-aktAnimalsMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutNF-kappa BOsteogenesisSignal TransductionIntegrin alphaVbeta3NF-kappa BProto-Oncogene Proteins c-aktbone diseasesbone resorptionF-actin cytoskeleton formationosteoclast differentiationswiprosin-1 (SWS1)/EFhd2

Identifiers

PMID40943533
PMCPMC12429813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.